Pasithea Therapeutics Corp - KTTA Book Capitalization

This price chart for Pasithea Therapeutics (KTTA) serves as an indicator for the company, which develops advanced drugs for neuroinflammation and depression, where patents and grants provide cash flow. The current figure is 0.05, however, the expansion of the development portfolio requires constant investment, increasing laboratory costs. The business faces intense pressure from industry behemoths that possess massive budgets for clinical trials.

For Pasithea Therapeutics (KTTA), which operates within an isolated biotechnological clinical trial cycle, this indicator reflects the actual net asset value by excluding market volatility. Analyzing the company's book capitalization chart allows an investor to assess equity dynamics: peaks signal the risk of overpayment, while a decline indicates the depletion of cash reserves necessary for the development of drugs treating depression and schizophrenia.